OVERVIEW HOPE-EPI: FCCSS F. de Vathaire PLATFORM OF THE NATIONAL REGISTRY OF CHILDHOOD CANCER. Etiology. RNCE National Registry J. Clavel, B.
|
|
- Clifford Boyd
- 5 years ago
- Views:
Transcription
1 : Epidemiological research in pediatric hemato-oncology-epidemiology ITMO Santé publique Paris Dr. Jacqueline CLAVEL M.D., Ph.D., Research Director at Inserm, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité OVERVIEW PLATFORM OF THE NATIONAL REGISTRY OF CHILDHOOD CANCER FCCSS F. de Vathaire Etiology RNCE National Registry J. Clavel, B. Lacour COHOPER Follow up LEA G. Michel, P. Auquier BIOCAP Virtual Biobank Treatments PEDIART V. Bernier COHORT INNOVATION DAY 71
2 LEADERSHIP s leadership team is set up with J. CLAVEL, F. de VATHAIRE, P. AUQUIER, and the representative of the National Network of Pediatric Oncologists (SFCE) Coordination of the Platform of the national registry since 2000 J. CLAVEL, M.D., Ph.D., Research Director Inserm, Paris-Descartes University Head of the team Epidemiology of child and adolescent cancers, UMRS 1153, Inserm Creator and Head of the National Registry of Childhood Hematopoietic malignancies Creation and direction of the program of research on environmental and genetic risk factors of childhood cancer More than 70 articles on childhood cancer in international journals over the last 10 year B. LACOUR, M.D., Ph.D., Research Director Inserm, Paris-Descartes University Member of the National Registry of Childhood Solid Tumors direction group 20 articles on childhood cancer in international journals over the last 10 years Coordination of the FCCSS cohort of solid Tumors F. de VATHAIRE, Ph.D., Research Director Inserm, Paris-Sud University Head of the Radiocarcinogenesis and IIatrogenic effects of Treatments team, UMRS 1018 Creation a radiotherapy dosimetry team which has set up several programs for the evaluation of the radiation doses received by various organs Extensive experience in cohorts in national and international contexts Coordination of two European projects addressing constitution of international cohorts 30 articles on the fate of childhood cancers survivors over the last 10 years Co-coordination of LEA cohort of Childhood Hematopoietic Malignancies since 1980 G. MICHEL, Pr. in Pediatrics, Timone (Marseille) Head of the Pediatric Hematology and Oncology Department Coordination of the inter-regional organization for recourse in pediatric oncology Chairs the SFCE Hematopoietic Stem Cell Transplant committee P. AUQUIER, M.D., Ph.D., Pr. in Epidemiology, Healthcare Economics and Prevention, Marseille North University Hospitals Head of the Public Health and medical information department, Co-director of the emergent Research Institute of Public Health-Inserm-Public Health Branch, Quality of Life and Chronic Diseases team Coordination of over 40 projects on quality of life (100 referenced articles on the same topic) SCIENTIFIC NETWORK & MANAGEMENT Collaboration network with European or International cohorts: > French network of pediatric oncology SFCE (the national network of pediatric oncologists): is being developed under the auspices of the SFCE in the work of the childhood cancer epidemiology > Research network with ENCCA (European Network for Cancer Research in Children and Adolescents), a project of observational clinical research based on registries founded by the European Commission through the 7 th Framework Program > Collaboration with European registries ACCIS (Automated Childhood Cancer Information System), ENCR (European Network of Cancer Registries), IACR (International Association of Cancer Registries), EuroCare (Childhood Cancer Survival in Europe, a European survival data bank) > Research network with International studies on risk factors (CLIC Childhood Leukemia International Consortium, I4C International Childhood Cancer Cohort Consortium) Through its Scientific Committee, implicates experts in: > Pediatric oncology: Jean Michon, President of SFCE (Scientific Committee President) and Dominique Valteau-Couanet, President of SFCE scientific board > Epidemiology of childhood cancer: Jacqueline Clavel ( coordinator - COHOPER and national registry) and Brigitte Lacour (COHOPER and national registry) > Epidemiology of radiation: Florent de Vathaire (FCCSS) > Quality of life, epidemiology and public health: Pascal Auquier (LEA) > Pediatric hemato-oncology: Gérard Michel (LEA) > Radiotherapy: Valérie Bernier (PEDIART) > Representative of Pancare (a FP7 European project studying the impact of treatment regimes on the long-term health of childhood cancer survivors), of the European Network for Cancer Research in Children and Adolescents (ENCCA), associations of parents and CNAM (French national health insurance) 72 COHORT INNOVATION DAY
3 RESEARCH COLLABORATION OPPORTUNITIES Phase IV Product approval Phase III Phase II Phase I Pre-clinical Proof of concept Translational research > Identification of environmental risk factors (exposures of the residence to radon, high-voltage power lines, road traffic, nuclear site, household waste incinerators, and other industrial sites) > Identification of genetic risk factors: (Genetic polymorphisms, gene-environment interactions) > Contribution to basic research projects by the BIOCAP virtual biobank Clinical development > Observational clinical research > Access to care and social inequalities: identification of potential limitations in access to care after the initial diagnosis or during relapses, the differences in management and their social and territorial determinants Outcomes research > Pharmaco-epidemiological studies: drug safety, real-world use, effectiveness, practices patterns, acceptance, risk/benefit, risk management > Long-term effects, sequels: data on the risk of second cancer and long-term effects (e.g. heart diseases) post-chemotherapy and radiotherapy > Quality of life studies: state of health, psycho-behavioral and cognitive development, quality of life, management and access to care BIBLIOGRAPHY Translational research > Sermage-Faure C, et al., Childhood leukaemia close to high-voltage power lines - the geocap study, Br J Cancer 2013; 108(9): > Amigou A, et al., Folic acid supplementation, MTHFR and MTRR polymorphisms, and the risk of childhood leukemia: The ESCALE study (SFCE). Cancer Causes Control 2012; 23(8): > Orsi L, et al., Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESCALE study (SFCE). Leukemia 2012 Translational research > Desandes E, et al., Pathways of care for adolescent patients with cancer in France from 2006 to Pediatr Blood Cancer 2011 Outcomes research > Alloin AL, et al., Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: An LEA study. Br J Haematol 2013 > Berbis J et al., A French cohort of childhood leukemia survivors: Impact of hematopoietic stem cell transplantation on health status and quality of life. Biol Blood Marrow Transplant 2013; 19(7): > Girard P, et al., Symptomatic osteonecrosis in childhood leukemia survivors: Prevalence, risk factors and impact on quality of life in adulthood. Haematologica 2013; 98(7): > de Vathaire F et al., Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: A retrospective cohort study. Lancet Oncol 2012; 13(10): > Haddy N, et al., Relationship between the brain radiation dose for the treatment of childhood cancer and the risk of long-term cerebrovascular mortality. Brain 2011; 134(Pt 5): > Minaya P, et al., The caregiver oncology quality of life questionnaire (cargoqol): Development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer. Eur J Cancer 2012; 48(6): COHORT INNOVATION DAY 73
4 : Focus on The Platform of the National Registry of Childhood Cancers (RNCE) Paris Dr Jacqueline CLAVEL M.D., Ph.D., Research Director at Inserm, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité OVERVIEW AT A GLANCE > All the cases of childhood cancers <18 years > National registry of childhood cancers: diagnosis, treatments, response to treatments > COHOPER cohort: follow-up of cases since 2000 > BIOCAP virtual biobank since 2011 > Coordinated by Jacqueline Clavel > Paris Descartes University sponsorship > Funded by ANR and INCa > Key words : cancer registry, childhood, risk factors, access to healthcare, cancer survivor, long term follow-up, quality of life KEY FACTS & FIGURES > National registry: 2,200 new cases per year > Cohort of survivors COHOPER: >> Inclusions and follow-up on-going in 40 centers >> Retrospective and prospective data collection >> 35,000 cases (all cases ) >> Medico administrative database linkage with SNIIRAM considered > Nationwide virtual biobanking BIOCAP: tumoral and constitutional specimens stored in hospital biobanks RNCE platform aims: To make available high quality transdisciplinary data (diagnosis, biology, treatments and follow-up) for research in pediatric oncology To increase knowledge on environmental and genetic risk factors, on iatrogenic effects of treatments and on short-, intermediate- and long-term state of health of people having suffered from childhood cancer Positioning > Collaboration with European Network for Cancer Research REGISTRY Childhood Cancer COHOPER Follow-up of all French cancer cases BIOCAP national virtual biobank Availability of early mortality and relapses data in children and adolescents as a work package leader/member dedicated to the contribution of registries to clinical research in pediatric oncology > Similar cohorts aiming to make available a the long-term follow-up of childhood cancer cases have just started in Europe COHORT INNOVATION DAY 74
5 PROJECT DESCRIPTION RNCE SCIENTIFIC OBJECTIVES Research on the risk factors for childhood cancer, the disparities in cancer management and their determinants, the iatrogenic effects of treatments, the short-intermediate and long term state of health of childhood cancer survivors and the determinants of their quality of life In consequence, ability to contribute to: > Primary prevention: prevention of exposure to environmental risk factors, genetic counseling and screening for genetic risk factors > Elucidation and prevention of potential inequalities in healthcare access related to social or territorial characteristics > Reduction of the diseases induced by treatment: screening for sequelae, and contribution to personalized follow-up of iatrogenic risks > Improvement in the management of cancer survivors > Improvement in the quality of life of cancer survivors > Improvement in treatments and post-marketing surveillance: risk/benefit ratio of future treatments through enhanced anticipation of their long-term effects INNOVATIVE SCIENTIFIC FEATURES Data collected thanks to the development and the enrichment of the high-performance tools held on a single platform Provides registry data, virtual biological collection and cohort data subject to high quality requirements Promotes the exchange of knowledge between epidemiology, fundamental, biology, genetics, clinical research and human and social sciences METHODOLOGY QUALITY Control of completeness based on the registry, with multiple independent sources (health insurance, hospital files, biology and pathology departments, clinical trials...), SOPs for data collection and data management International rules of cancer registration and coding, INCa rules of registration of biobanking items Labelisation by the Registries Evaluation Committee (last 5-year renewal in 2014) COHORT INNOVATION DAY 75
6 DESIGN, METHODOLOGY & TIMELINE RNCE REGISTRY First patient BIOCAP National virtual biobank COHOPER retrospective cohort First patient REGISTRY Evaluation of the data exhaustiveness Opening data Availability of COHOPER early mortality and relapses data Recruitment objectives: 35,000 cancer cases expected in 2020 Sites: Inclusion criteria: 40 centers widespread on the French territory 70 laboratories (BRCs and pathology labs) <18 years All cancers in compliance with national and international criteria France and overseas departments (Guyane, Réunion, Martinique, Guadeloupe) INCLUSION COLLECTION Database: socio-demographic, geolocation, diagnosis, treatment, responses to treatments, health care system Virtual biobank: information related to tissues, cells, blood, serum, plasma, DNA and RNA, collected from patients and stored in the hospital biobanks FOLLOW-UP: COHOPER collects follow-up data from 3 years after the diagnosis. BIOCAP is supplied once a year with all informations regarding the newly collected biospecimens Database: events (relapses, second cancers, deaths), health (medical records, questionnaires and medico-administrative databases) Virtual biobank: information related to tissues, cells, blood, serum, plasma, DNA, RNA collected from patients notably in case of relapses or second cancers, and stored in the hospital biobanks 76 COHORT INNOVATION DAY
7 DATABASE CONTENTS RNCE PATIENT BIOPSY DIAGNOSIS TREATMENT TYPE RESPONSE TREATMENT FOLLOW-UP SAMPLE RELATED BIOLOGICAL MATERIAL ADDITIONAL VARIABLE DESCRIPTION REGISTRY and COHOPER Patient identification number, Name, Forename, Date of birth, Sex, Vital status, Medical centers Date of diagnosis, Histology, Cytology, Cytogenetics, Immunophenotype, Molecular biology, Topography, Staging (/classification) Coding (ICD-O and ICCC) Healthcare pathway, VARIABLE DESCRIPTION BIOCAP (virtual biobank) Patient identification number, Name, Forename, Date of birth, Sex, Vital status, + Consent status Hospital name, Hospital ID (National files of Social and Health Institutions), Hospital department, Biopsy ID, Biopsy date, Biopsy time, Date of biopsy receipt, Biopsy collection mode, Biopsy type Disease ontology, Classification of International diseases (CIM) 0/Systematized NOmenclature of MEDicine (SNOMED) Organ category, CIM0/SNOMED Histopathological grading, Association of computerization development in Cytology and Anatomopathology (ADICAP) edition, ADICAP Organ category, ADICAP, Tumoral grade Histopathological grading, Tumoral stage, ptnm edition, pt, pn, pm, Disease Stage Risk classification, Date treatment started, Protocol arm, Chemotherapy (date, drugs, cumulative doses), Surgery (date, type and site), Radiotherapy (date, type, site and dose), Stem cell transplantation (date, type and source) Resection adequacy, Necrosis extent/early MRD bone marrow, Date treatment completed Date of last contact, Date, Site of relapse, Date of blast transformation, Date, cause of death Sample collection ID, Tumoral, Conservation mode, Biospecimen type, Processing method, Delay of freezing, Freeze date, Freeze time, Control tissue, Control precision, Number of aliquots, Tumor cell percentage, cdna, DNA extraction protocol, crna, RNA extraction protocol, Derived proteins, Repository name, Repository ID (National files of Social and Health Institutions) Serum, Plasma, Whole blood, Other liquid, Other liquid / type, Constitutionnal DNA, Repository name, Repository ID (National files of Social and Health Institutions) Clinical trials, PMSI, Death Standard diagnostic pathology report available, Associated clinical data, Therapeutic protocol inclusion, Research protocol inclusion, Sample delivery, Number of required tubes, Delivery date, Destination assignment, Delivery purpose BIOCAP THE PLATFORM VIRTUAL BIOBANK Originality > BIOCAP is a virtual biobank, leaned on the National Registry of Childhood Cancers > BIOCAP allows to get access to the overall information regarding each biospecimens collected from patients during their current cares and hosted into a hospital biobank of a BRCs or an anapath labs participating to the project > Strengths: permanent, sustainable collection, exhaustiveness (all childhood cancers in France) > Quality: clinical annotations and control procedures are set up Scientific objective > Facilitate project on rare tumors spread over the national territory (identification, documentation of the cases) > Project on prognosis for different types of tumors with a common transcript > Oncogenesis molecular mechanisms > Prognostic value of molecular markers > Environmental (road traffic, background radiation...) and genetic risk factors of childhood cancers Samples > Nature of the biospecimens : tissue, biopsies, cells, blood, serum, plasma, DNA and RNA > First sampling-data in BIOCAP: >> From January 1 st 2009 (Paris area) >> From January 1 st 2011 (other regions) > 3,5 samples per patient > Data on biospecimens stored are already collected for 2,600 patients (10,000 specimens in total) > 2,200 patients with specimens expected each year > BIOCAP update: once a year, with the data associated to the newly collected biospecimens Associated resources > The resources to exploit the biospecimens depend on the human resources and the know-how of each center that hosted the local biobank COHORT INNOVATION DAY 77
8 BIOCAP - TECHNICAL MODALITIES & SPECIFICATIONS BIOBANK SAMPLE ACCESS MODALITIES BIOCAP Scientific responsible: Dr. Jacqueline Clavel BIOCAP opening to the research community from June 2016 To access to BIOCAP, industrials as academic teams are invited to apply to the scientific call of the Platform planned in June 2016 for the first and every 6 months thereafter. BIOCAP access modalities are specified in the charter written in the context of and available BIOLOGICAL SAMPLE ANALYSES Each local biobank center is responsible for its biospecimens, follows specific procedures (SOPs) for their treatment process, ensuring their safe transport and uses its proper identification system Access to biospecimens for investigators, after successful access to BIOCAP database, requires specific agreements with the local biobank centers, with the support of the platform coordination COST The financial estimation of the biospecimens is still under discussion, with reference to the BIOBANQUE program BIOCAP - BIOLOGICAL SPECIMENS IN THE VIRTUAL BIOBANK ICCC diagnosis group Patient with at least 1 specimen Specimens by 1 1 nontumoral specimen (mean) Any patient tumoral 1. Leukemias 1, ,440 4,0 2. Lymphoma ,7 3. Brain tumors ,0 4. Neuroblastomas ,6 5. Retinoblastomas ,5 6. Renal tumors ,5 7. Hepatic tumors ,6 8. Malignant bone tumors ,6 9. Soft tissue tumors ,1 10. Germ cell tumors, gonads ,9 11. Carcinomas ,5 TOTAL 3, ,066 4,4 78 COHORT INNOVATION DAY
9 : Focus on the LEA cohort (Childhood and Adolescent Leukemia) Prof. Gérard MICHEL Head of pediatric onco-hematology department La Timone Hospital Marseille Marseille Prof. Pascal AUQUIER Head of EA 3279, Public Health Department Aix Marseille University OVERVIEW AT A GLANCE > Onco-hematology and quality of life > Malignant haematological diseases, particularly Acute Leukaemia (AL) > Children treated for AL since January 1980, surviving at 24 months for myeloblastic AL and lymphoblastic AL grafted in first complete remission > Coordinated by Prof. P. Auquier, Prof. G. Michel > AP-HM (Assistance Publique-Hôpitaux de Marseille, Marseille University Hospitals) > Funded by ANR > Key words: childhood leukemia, quality of life, late effects, late outcomes KEY FACTS & FIGURES > Inclusion on going > More than 3,000 expected patients > More than 3,400 included patients by now > Follow-up is planned until included patients are 50 years-old > National multicentric cohort (actually 16 paediatric onco-haematology units are involved in the project) > No biobank until now LEA aims at studying the determinants (medical, socioeconomic, behavioral and environmental) of a medium and long-term outcomes of patients treated for AL. First patient included Inclusion on going From 2016 Data Analysis Positioning > LEA is involved in a PanCare project > Coordinators are implicated in others epidemiologic studies: MuSIQoL Cohort (Multiple Sclerosis International Quality Of Life Cohort), SQoL (Schizophrenia Quality Of Life questionnaire), PLH Study (PolyHandicap Study), UCSA (Un Chez Soi d Abord - French Housing First Program) COHORT INNOVATION DAY 79
10 LEA - DATABASE CONTENT Clinical, medical, biological, socioeconomic, demographic, social insertion and environmental data Quality of life of the patients and their parents (if patient under 18) Imagery data > Thyroid Echography >> Global result normal/abnormal, thyroïdian nodule or not, date of discovery, cytologic analysis yes or no -> if yes result of the cytological analysis and type of therapeutic care >> Available for 839 patients > Cardiac echography >> Global result normal /abnormal, date of discovery if abnormal, shortenning fraction and left ventricular ejection fraction, medical treatment or not and which one, cardiac graft or not and date >> Available for 3,363 patients > Bone densitometry >> Global result normal /abnormal, date of discovery if abnormal, BM.D., T score, Z score, medical treatment or not and which one; >> Available for 2,179 patients > Hepatic MRI >> Hepatic iron concentration >> Available for 45 patients COHORT INNOVATION DAY 80
General. Identification. Loire-Atlantique/Vendée cancer registry (registre. Detailed name. qualifié)
EPIC-PL - Loire-Atlantique/Vendée cancer registry (registre qualifié) Head : Molinié Florence Last update : 09/08/2017 Version : 1 ID : 224 General Identification Detailed name Sign or acronym CNIL registration
More informationRisk factors of childhood leukemia: the French research program
Risk factors of childhood leukemia: the French research program Dr Jacqueline Clavel Director, research unit of Environmental Epidemiology of Cancer INSERM, Paris-Sud University National Registry of Childhood
More informationPositioning. > MEMENTO is a large observational study enrolling patients at an. Data first availability for project analyses
: determinants and Evolution of AlzheiMer s disease and related disorders ITMO Santé publique OVERVIEW AT A GLANCE Bordeaux Geneviève Chêne, MD, PhD Professor of Biostatistics and Public Health, Bordeaux
More informationA risk assessment of the potential impacts of radon, terrestrial gamma and cosmic rays on childhood leukaemia in France
A risk assessment of the potential impacts of radon, terrestrial gamma and cosmic rays on childhood leukaemia in France Olivier LAURENT 1, Sophie ANCELET 1, Géraldine IELSCH², Denis HEMON 3,4, Jacqueline
More informationThe University of Chicago Childhood Cancer Survivors Project
PROTOCOL NUMBER:15587B Version date 08/27/2008 TITLE: The University of Chicago Childhood Cancer Survivors Project PRINCIPAL INVESTIGATOR: Tara Henderson, M.D., M.P.H. Instructor of Pediatrics Director,
More informationHAUT-RHIN CANCER REGISTRY
ARER 68 - HAUT-RHIN CANCER REGISTRY Head : Marrer Emilie Last update : 07/30/2014 Version : 1 ID : 4865 General Identification Detailed name HAUT-RHIN CANCER REGISTRY Sign or acronym ARER 68 CNIL registration
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology
ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology ACGME approved: June 27, 2006; effective: July 1, 2007 ACGME approved focused revision: September 30, 2012; effective:
More informationLate complications after hematopoietic stem cell transplant in adult patients
Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France Synopsis H S C T Allogeneic HSCT activity
More informationSurvival Inequalities among Children, Adolescents and Young Adults with Acute Leukemia in California Renata Abrahão, MD MSc PhD
Survival Inequalities among Children, Adolescents and Young Adults with Acute Leukemia in California Renata Abrahão, MD MSc PhD California Cancer Registrars Association Sacramento November 3 rd, 2016 Objectives
More informationFrench registry of pleural mesothelioma cases
MESONAT - French registry of pleural mesothelioma cases Head : Galateau-Salle Françoise, Groupe Mésopath. Laboratoire d'anatomie PATHOLOGIQUE, CHU CAEN 14033 Caen CedexERI 3 Inserm?'Cancers et Populations''
More informationThe National Cancer Dataset Initiative ddd CTYA SSCRG. Di Riley Associate Director for Clinical Outcomes
The National Cancer Dataset Initiative ddd CTYA SSCRG Di Riley Associate Director for Clinical Outcomes CRS, December 2007...Better information on cancer services and outcomes will enhance patient choice,
More informationPanCareSurFup Bulletin, Issue nr. 5
March 2014 PanCareSurFup Bulletin, Issue nr. 5 PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Dear Friends, Since the last Bulletin in December 2013, the project has been busy
More informationReporting of Cancer Stage Information by Acute Care Hospitals in Ontario
Reporting of Cancer Stage Information by Acute Care Hospitals in Ontario Forward This document is an accompanying reference to Ontario s staging policy entitled Guidelines for Staging Patients with Cancer
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationSurvival Rates of Childhood Cancer Patients in Osaka, Japan
Jpn J Clin Oncol 2004;34(1)50 54 Epidemiology Note Survival Rates of Childhood Cancer Patients in Osaka, Japan Wakiko Ajiki, Hideaki Tsukuma and Akira Oshima Department of Cancer Control and Statistics,
More informationNUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow
Quality ID #67 (NQF 0377): Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow National Quality Strategy Domain: Effective Clinical Care
More informationCurrent system of childhood cancer registration in Belarus
doi:10.2478/v10019-007-0038-1 Current system of childhood cancer registration in Belarus Natallia N. Savva, Anna A. Zborovskaya, Olga V. Aleinikova Belarusian Research Center for Pediatric Oncology and
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: ASP 2215-cl-0101 Previous Study Return to List Next Study Dose Escalation Study Inv e stigating the Safe ty, Tole rability,
More informationSecond Neoplasms Working Group. CCSS Investigators Meeting June 2017
Second Neoplasms Working Group CCSS Investigators Meeting June 2017 Second Neoplasms Working Group Overview Ongoing review, adjudication and entry of reported neoplasms into data set Initial review of
More informationANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C
ANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C Head : Nahon Pierre, Service d'hépatologie, Hôpital Jean Verdier Roudot-thoraval Françoise, Service de santé publique,
More informationSolid tumors in young children in Moscow Region of Russian Federation
doi:10.2478/v10019-007-0037-2 Solid tumors in young children in Moscow Region of Russian Federation Denis Y Kachanov 1,2, Konstantin V Dobrenkov 2, Tatyana V Shamanskaya 1,2, Ruslan T Abdullaev 1,2, Evgueniya
More informationCancer in adolescents and Young Adults
17 th ESO-ESMO Masterclass in Clinical Oncology 24-29 March 2018, Cancer in adolescents and Young Adults Laurence Brugières Gustave Roussy Cancer Center Villejuif, France Cancer in TYA A rare disease in
More informationShared Care & Survival CTYA SSCRG (Childhood Cancer Research Group)
Shared Care & Survival CTYA SSCRG (Childhood Cancer Research Group) January 2013 The NCIN is a UK-wide initiative, working to drive improvements in standards of cancer care and clinical outcomes by improving
More informationSurvivorship After Stem Cell Transplantation and Long-term Followup
Survivorship After Stem Cell Transplantation and Long-term Followup Navneet Majhail, MD, MS Director, Blood & Marrow Transplant Program, Cleveland Clinic Professor, Cleveland Clinic Lerner College of Medicine
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA
ONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA 1Rosline H, 1Majdan R, 1Wan Zaidah A, 1Rapiaah M, 1Selamah G, 2A A Baba, 3D M Donald 1Department of Haematology, 2Department
More informationThe New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process
The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process Wednesday, April 29, 2009 at 11 AM Central M. Asa Carter, CTR Manager, Approvals and Standards
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationThe French National Rare Diseases Registries BNDMR-BaMaRa and RaDiCo
The French National Rare Diseases Registries BNDMR-BaMaRa and RaDiCo Pr Paul Landais Montpellier 1 University, EA 2415, Faculty of Medecine Nîmes University Hospital, France National Databank for RaRe
More informationLLR Childhood Leukaemia CellBank Anne Thomson, CellBank Manager..org.uk
LLR Childhood Leukaemia CellBank Anne Thomson, CellBank Manager.org.uk Purpose To facilitate high quality translational research in childhood leukaemia: clinical and basic science Centralised specialist
More informationA risk assessment of the potential impacts of radon, terrestrial gamma and cosmic rays on childhood leukemia in France
A risk assessment of the potential impacts of radon, terrestrial gamma and cosmic rays on childhood leukemia in France Olivier LAURENT 1, Sophie ANCELET 1, Géraldine IELSCH 1, Denis HEMON 2, Jacqueline
More informationI.2 CNExT This section was software specific and deleted in 2008.
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I Changes and Clarifications 8th th Edition Revised May 2008 SECTION
More informationRIC-Mel Network - Network for Research and Clinical Investigation on Melanoma - French national cohort of
RIC-Mel Network - Network for Research and Clinical Investigation on Melanoma - French national cohort of melanoma patients Head : Pr Dreno Brigitte, INSERM Unité U892 Equipe 2 «Recherche clinique et translationnelle
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationLong-term PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs
Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs EMEA meeting, december 4, 2009 A European collaboration between pediatric rheumatology centers
More informationPHARMO Database Network
Pros & cons in Oncology studies PHARMO Myrthe Database van Herk-Sukel, Network PhD 1 Disclosure Myrthe van Herk-Sukel is an employee of the PHARMO Institute for Drug Outcomes Research. This independent
More informationRole of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care
4 th International Congress of Breast Role of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care Adri C. Voogd, PhD, epidemiologist Department of Epidemiology, Maastricht University
More informationLong-Term Outcomes After Hematopoietic Cell Transplantation
Long-Term Outcomes After Hematopoietic Cell Transplantation Conflicts of Interest No relevant financial conflicts of interest Navneet Majhail, MD, MS Medical Director, NMDP Assistant Scientific Director,
More informationSCIENTIFIC TIMETABLE SIOP 2015
SCIENTIFIC TIMETABLE SIOP 2015 September, 2015 WEDNESDAY, 7 TH OCTOBER 2015 / DAY 2 1.43 09:30 SIOP Committee 12:00 SIOP Essential Drugs Working 13:00 SIOP Work (Open) 14:00 Nurse Researchers 16:00 17:00
More informationRESEARCH COMMUNICATION. Childhood Cancer Incidence and Survival , Thailand: Study from the Thai Pediatric Oncology Group
Childhood Cancer Incidence and Survival 2003-2005, Thailand RESEARCH COMMUNICATION Childhood Cancer Incidence and Survival 2003-2005, Thailand: Study from the Thai Pediatric Oncology Group Surapon Wiangnon
More informationREGULATIONS FOR THE POSTGRADUATE DIPLOMA IN MOLECULAR AND DIAGNOSTIC PATHOLOGY (PDipMDPath)
REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN MOLECULAR AND DIAGNOSTIC PATHOLOGY (PDipMDPath) (See also General Regulations and Regulations for Taught Postgraduate Curricula) M.129 Admission requirements
More informationITCC-P4 International Workshop
ITCC P4 GA No. 116064 ITCC-P4 International Workshop IMPROVING PEDIATRIC ONCOLOGY DRUG DEVELOPMENT THROUGH PRECLINICAL RESEARCH September 27 th and 28 th, 2018 // Amsterdam, NL By invitation The event
More informationLinkage of Indiana State Cancer Registry and Indiana Network for Patient Care
Linkage of Indiana State Cancer Registry and Indiana Network for Patient Care A collaboration between Regenstrief Institute, Indiana University, and the Indiana State Cancer Registry Objectives Understand
More informationTHE GUSTAVE ROUSSY / INSERM PLATFORM
Retrospective dose reconstruction in external beam radiotherapy for use in epidemiology: THE GUSTAVE ROUSSY / INSERM PLATFORM Dimitri Lefkopoulos PhD, Medical Physics Medical physics Department Gustave
More informationAnalytical and economic evaluation of the fully automated Xpert BCR-ABL assay from Cepheid
Analytical and economic evaluation of the fully automated Xpert BCR-ABL assay from Cepheid Jean-Michel Cayuela Saint-Louis hospital Paris July 5, 2012 Talk outline Chronic myeloid leukemia > Genetic bases,
More informationThis section allows identifying the facility, this information is important for data quality follow up. Source of Standard. Source of Standard
Data Dictionary Case Administration This section allows identifying the facility, this information is important for data quality follow up Facility Name This identifier is needed to evaluate This data
More informationBase Anatomo Clinique de l Adénocarcinome Pancréatique
Base Anatomo Clinique de l Adénocarcinome Pancréatique Coordinator Dr BOURNET Barbara Project Manager Cindy Canivet Service de Gastroentérologie et Nutrition CHU de Toulouse Aims of BACAP Incidence rate
More informationSubspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident
Subspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident Residents: Pediatric residents at the PL3 level Prerequisites: Successful completion or waiver
More informationA Summary of Childhood Cancer Statistics in Australia,
What is the Australian Paediatric Cancer Registry (APCR)? The APCR is one of only a few national registries of childhood cancer in the world. It covers all Australian children aged 0-14 years old at diagnosis.
More informationIntroduction Cancer is a major public health threat in Switzerland.
National law on cancer registration in Switzerland: Background information from NICER and the cantonal cancer registries regarding the importance of data collected for the purpose of cancer monitoring
More informationCANCER CARE IN LUXEMBOURG
CANCER CARE IN LUXEMBOURG Dr Berchem Guy MD Dr Duhem Caroline MD Hematology-Oncology Department Centre Hospitalier de Luxembourg CANCER CARE in LUXEMBOURG Current population (2005) = 468,571 residents
More informationHAEMATOLOGICAL MALIGNANCY
HAEMATOLOGICAL MALIGNANCY Reference Compulsory reading Haematology at Glance 2 nd ed. Atul Mehta & Victor Hoffbrand Chapters: 20 to 31 Pages: 46 to 69 Pathogenesis of Haematological Malignancy Figure (a)
More informationSignificant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions
Significant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions Susannah E. Koontz, PharmD, BCOP Clinical Pharmacy & Education Consultant Pediatric Hematology/Oncology and
More informationPHOTO. VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe
www.eurordis.org VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe Lucca ( Italy ) March 13-14, 2008 PHOTO www.eurordis.org
More informationPediatric Cancer in Idaho,
Pediatric Cancer in Idaho, 1996-2006 Although relatively rare in comparison with cancer in older adults, cancer is the second leading cause of death in persons aged 1-14 years. The epidemiology of cancer
More informationHaematopoietic stem cell transplantation (SCT)
HAEMATOPOIETIC TEM CELL TRANPLANTATION FOR CHILREN IN BELGIUM Marie-Françoise resse 1 & Yves Beguin 2 1 epartment of Paediatrics, ivision of Hemato-Oncology, UHOPL, University of Liege, Liège, Belgium;
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationNew Surgical Oncology Clinic at Nationwide Children s Hospital
Hematology/Oncology & BMT New Surgical Oncology Clinic at Nationwide Children s Hospital This clinic offers convenient, comprehensive care for patients with cancer. Here, in one visit, pediatric patients
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationQuestion. Lillian Sung MD, PhD. The Hospital for Sick Children. February 10, 2017
Defining the Clinical Trial Question Lillian Sung MD, PhD Chair, CYP-C C Management Committee The Hospital for Sick Children CYP-C Research Champion Educational Series February 10, 2017 No financial Disclosures
More informationR&D UNICANCER Oncology Research
R&D UNICANCER Oncology Research R&D UNICANCER A national academic sponsor dedicated to clinical research in oncology Our missions: Promote and accelerate Clinical Research in Oncology, especially in areas
More informationThe Development of Pediatric Oncology in Turkey:
The Development of Pediatric Oncology in Turkey: Improving Childhood Cancer Survival Rate Through Professional Training and Education Prof. Dr. Tezer Kutluk, MD PhD, FAAP UICC president & Hacettepe University
More informationA tumor profile and adapted cancer surveillance in Down syndrome
A tumor profile and adapted cancer surveillance in Down syndrome Daniel Satgé Pathology, University Hospital, Saint Etienne, France and ONCODEFI Project IURC Montpellier, France Michel Vekemans Labratory
More informationCertificate of Advanced Studies in Personalized Molecular Oncology
Certificate of Advanced Studies in Personalized Molecular Oncology Certificate of Advanced Studies (CAS) in Personalized Molecular Oncology Overview Cutting-edge technologies, like next-generation-sequencing
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationResults of LSA2-L, Therapy in Children with High-Risk Acute Lyrnphoblastic Leukemia and Non-Hodgkin's Lymphoma *
Haematology and Blood Transfusion Vol. 28 Modem Trends in Human Leukemia V Edited by Neth, Gallo, Greaves, Moore, Winkler @ Springer-Verlag Berlin Heidelberg 1983 Results of LSA2-L, Therapy in Children
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationStem cell Survivorship: Searching for a solution to our success. Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic
Stem cell Survivorship: Searching for a solution to our success Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic Location of Centers Participating in t he CI BMTR 2 0 0 7................................................................................................................
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationCHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in Survivors of Childhood Leukemia with Down Syndrome Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in of Childhood Leukemia with Down Syndrome Analysis Concept Proposal Working Group and Investigators Genetics Working Group & Chronic Disease Working
More informationCAP Accreditation of Genetics Testing Laboratories
CAP Accreditation of Genetics Testing Laboratories Secretary s Advisory Committee on Genetics, Health, And Society March 26, 2007 Gail Vance, MD, FCAP College of American Pathologists Overview Shared Goals
More informationHematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow This measure may be used as an Accountability measure Clinical Performance
More informationDISPARITIES IN PEDIATRIC CANCER CARE
Disclosure DISPARITIES IN PEDIATRIC CANCER CARE Anne Marie Langevin MD has no relationships with commercial companies to disclose. Anne-Marie Langevin, MD Hematologist/Oncologist Professor of Pediatrics
More informationLong-term PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs
Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs EMEA meeting, june 28, 200 A European collaboration between pediatric rheumatology centers regarding
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationRHU ivasc: CONSTANCES et la recherche cardiovasculaire. Ph.Gabriel STEG DHU FIRE Hôpital Bichat; AP-HP INSERM U1148 Université Paris Diderot
RHU ivasc: CONSTANCES et la recherche cardiovasculaire Ph.Gabriel STEG DHU FIRE Hôpital Bichat; AP-HP INSERM U1148 Université Paris Diderot ivasc: Innovations in atherothrombosis science Atherothrombosis:
More informationChanging the prevention paradigm for the future what Europe can do
November 3rd, 2014 Honorable Beatrice Lorenzin, Minister of Health of Italy Italian Presidency of the EU Council Conference/Meeting The State of Health of Vaccination in the EU: where do we stand, where
More informationnuclear science and technology
EUROPEAN COMMISSION nuclear science and technology Gene-radiation interactions: their influence on pre-menopausal breast cancer risk after Chernobyl (GENE-RAD-INTERACT) Contract N o FIGH-CT2002-00215 Final
More informationSurvival in Teenagers and Young. Adults with Cancer in the UK
Survival in Teenagers and Young Adults with Cancer in the UK Survival in Teenagers and Young Adults (TYA) with Cancer in the UK A comparative report comparing TYA cancer survival with that of children
More information10/16/2014. Adolescents (ages 10 19) and young adults (ages 20 24) together compose about 21% of the population of the United States.
The purview of pediatrics includes the growth, development, and health of the child and therefore begins in the period before birth when conception is apparent. It continues through childhood and adolescence
More informationLate effects, health status and quality of life after hemopoietic stem cell
Late effects, health status and quality of life after hemopoietic stem cell transplantation (HSCT) THE 13th ESH-EBMT TRAINING COURSE ON BLOOD AND MARROW TRANSPLANTATION EBMT Slide template Barcelona 7
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationA Comprehensive Approach to. International Cancer Survival Benchmarking. SurvMark-2
A Comprehensive Approach to International Cancer Survival Benchmarking SurvMark-2 Call for Data Data specification June 2016 The deadline for data submission will be 15 September 2016 and it is essential
More informationVictorian Paediatric Oncology Situational Analysis & Workforce Requirements
- Victorian Paediatric Oncology Situational Analysis & Workforce Requirements 2012-2026 SUMMARY REPORT May 2013 1 Contents Executive summary...3 1. Introduction...6 2. Project method...8 2.1 Estimating
More informationRadiation doses and cancer incidence (excluding thyroid cancer) due to the Chernobyl accident
Radiation doses and cancer incidence (excluding thyroid cancer) due to the Chernobyl accident Eva Forssell-Aronsson Dept of Radiation Physics Inst of Clinical Sciences Sahlgrenska Academy University of
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationThe 100,000 Genomes Project
The 100,000 Genomes Project Dr Matina Prapa, Scientific co ordinator Genomics England Clinical Interpretation Partnership William Harvey Research Institute Queen Mary University of London Genomics England
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationOverview of 2013 Hong Kong Cancer Statistics
Overview of 2013 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry (HKCaR) is a population-based cancer registry, collecting the basic demographic data, information
More informationScottish Medicines Consortium
Scottish Medicines Consortium clofarabine, 1mg/ml concentrate for solution for infusion (Evoltra ) (No. 327/06) Bioenvision Limited 8 December 2006 The Scottish Medicines Consortium (SMC) has completed
More informationTUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)
Legend: Keynote Educational Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite SIOPe GA SIOP ABM Late Breaker Session Networking
More informationEXCELLENCE AND INNOVATION
EXCELLENCE AND INNOVATION FOR CANCER TREATMENT THE CENTRE LÉON BÉRARD Non-profit private health care facility of public interest (ESPIC), affiliated with the French National Cancer Center Federation UNICANCER
More informationCLINICAL RESEARCH IN GEORGIA UPDATE. Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014
CLINICAL RESEARCH IN GEORGIA UPDATE Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014 Georgia CORE is a public-private partnership dedicated to generating collaborative resources for
More informationCancer Science nd International Conference on Oncology & Cancer Science. August 06-08, 2018 Berlin, Germany. Hosting Organization
Cancer Science 2018 2nd International Conference on Oncology & Cancer Science August 06-08, 2018 Berlin, Germany Hosting Organization Invitation Cenetri Publishing Group takes keen delectation and highly
More informationIntroduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT
Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT protocols Tips Leukaemia / lymphoma: ~ 35% acute lymphoblastic
More informationPGY-2 ONCOLOGY RESIDENCY ROTATION DESCRIPTION
PGY-2 ONCOLOGY RESIDENCY ROTATION DESCRIPTION ROTATION TITLE Outpatient Adult Oncology PURPOSE The outpatient oncology service will provide the PGY-2 resident with the opportunity to further develop and
More informationThe European Reference Network in Rare Hematological Diseases
The European Reference Network in Rare Hematological Diseases Pierre Fenaux ERN-EuroBloodNet coordinator www.eurobloodnet.eu The context of ERNs Share. Care. Cure. Due to the small patient number and the
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 19 Dec 2018 02:45:15 GMT) CTRI Number Last Modified On 25/12/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More information2018 IMPLEMENTATION UPDATE: WHAT S NEW IN STAGING FOR 2018?
2018 IMPLEMENTATION UPDATE: WHAT S NEW IN STAGING FOR 2018? SESSION 2 10/20/17 Q&A Please submit all questions concerning webinar content through the Q&A panel. A recording of today s session, the Q&A,
More information